Skip to main content
SpringerLink
Log in
Book cover

Obesity pp 401–424Cite as

Medications Indicated for Chronic Weight Management

  • Reference work entry
  • First Online:

  • 1708 Accesses

Part of the book series: Endocrinology ((ENDOCR))

Abstract

This chapter reviews the medications currently available for chronic weight management in the USA and some other countries and, for those five medications, discusses mechanism of action, efficacy data, and safety profiles. The chapter also discusses principles of prescribing and best practices for managing patients with medications indicated for weight management. Four of the newer agents (lorcaserin, liraglutide 3.0 mg, naltrexone SR/ bupropion SR, and phentermine/topiramate ER) all act primarily in the central nervous system. They regulate appetite and reduce food intake to help patients better adhere to a dietary plan. Orlistat acts peripherally to block absorption of 30% of ingested fat and reinforces adherence to a low-fat diet, thus reducing energy intake. These five newer medications are intended for long-term use to help patients not only lose more weight than with lifestyle changes alone, but also to maintain hard-won weight losses. Best practices in chronic disease prevention and management currently require physicians to help patients manage weight as a pathway to health improvement and those patients who struggle with weight and would derive health benefits from weight loss are candidates for medications. A current trend is to intervene earlier with these medications, especially with patients at higher health risk. The available medications have differing profiles in safety, efficacy, and tolerability. No one medication is right for every patient and the patient’s profile must be matched to the medication profile. Thus, providers caring for patients with obesity-associated risk and diseases should be knowledgeable on how to prescribe for chronic weight management. Finally, if patients have success with a medication and lifestyle change to produce weight loss, the medication should be continued to maintain weight loss. Since weight regain is an issue when medications are stopped, restarting medications is also appropriate.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   349.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Alli™ product label, US Food and Drug Administration. https://www.accessdata.fda.gov/-drugsatfda_docs/label/2007/021887lbl.pdf. Accessed 15 Apr 2017.

  • Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330–42.

    Article  CAS  Google Scholar 

  • Apovian CM, Aronne LA, Rubino D, COR-II Study Group, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity related risk factors (COR-II). Obesity. 2013;21:935–43.

    Article  CAS  Google Scholar 

  • Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH, Still CD. Endocrine Society. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015a;100(2):342–62. Erratum in: J Clin Endocrinol Metab 2015 May;100(5):2135–6.

    Article  CAS  Google Scholar 

  • Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH, Still CD, Endocrine Society. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015b;100(2):342–62.

    Article  CAS  Google Scholar 

  • Belviq® prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs-/label/2012/022529lbl.pdf. Accessed 15 Apr 2017.

  • Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes. 2016;40:1310–9.

    Article  CAS  Google Scholar 

  • Bray GA. Some historical aspects of drug treatment for obesity. In: Wilding JPH, editor. Pharmacotherapy of obesity. Basel: Burkhauser-Verlag; 2008. p. 11–9.

    Chapter  Google Scholar 

  • Bray G, Greenway F. Pharmacological treatment of the overweight patient. Pharmacol Rev. 2007;59:151–84.

    Article  CAS  Google Scholar 

  • Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes. 2001;2(7):1095–9.

    Article  Google Scholar 

  • Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293(23):2873–83.

    Article  CAS  Google Scholar 

  • Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA’s assessment of two drugs for chronic weight management. N Engl J Med. 2012;367(17):1577–9.

    Article  CAS  Google Scholar 

  • Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical evaluation of medicinal products used in weight management. 23 June 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500209942.pdf. Accessed 15 Apr 2017.

  • Contrave® FDA prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200063s000lbl.pdf. Accessed 15 Apr 2017.

  • Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314:687–99.

    Article  CAS  Google Scholar 

  • Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–77.

    Article  CAS  Google Scholar 

  • Flegal KM, Carroll RJ, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes. 1998;22(1):39–47.

    Article  CAS  Google Scholar 

  • Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.

    Article  CAS  Google Scholar 

  • Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.

    Article  CAS  Google Scholar 

  • Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R, Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of endocrinology comprehensive clinical practice guidelines for medical Care of Patients with obesity. Endocr Pract. 2016a;22(7):842–84. Executive Summary. Complete guidelines available at https://www.aace.com/publications/guidelines

    Article  Google Scholar 

  • Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016b;22(Suppl 3):1–203.

    Article  Google Scholar 

  • Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009;17(1):30–9.

    Article  CAS  Google Scholar 

  • Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605.

    Article  CAS  Google Scholar 

  • Guidance for industry developing products for weight management. Draft Guidance. US Department of Health and Human Services, Food and Drug Administration, February 2007, Revision 1. https://www.fda.gov/downloads/Drugs/Guidances/ucm071612.pdf. Accessed 15 April 2017.

  • http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002597/wapp/Initial_authorisation/human_wapp_000165.jsp&mid=WC0b01ac058001d128. Accessed 17 Jun 2017.

  • http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002350/WC500144300.pdf. Accessed 17 Jun 2017.

  • Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs. 2007;67(1):27–55.

    Article  CAS  Google Scholar 

  • Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376:254–66.

    Article  CAS  Google Scholar 

  • Hollander P, Gupta AK, Plodkowski R, et al for the COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–9.

    Article  Google Scholar 

  • Jensen MD, Ryan DH, Donato KA, et al. Guidelines (2013) for managing overweight and obesity in adults. Obesity. 2014;22(S2):S1–S410.

    Article  Google Scholar 

  • Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events. A systematic review and meta-analysis. JAMA. 2016;315:2424–34.

    Article  CAS  Google Scholar 

  • Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life in obesity. Obes Res. 2001;9:102–11.

    Article  CAS  Google Scholar 

  • Le Roux CW, Astrup A, Fujioka K, et al for the show SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomized, double-blind trial. Lancet. 2016;389(10077):1399–409.

    Google Scholar 

  • Leblanc ES, O’Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. preventive services task force. Ann Intern Med. 2011;155(7):434–47.

    Article  Google Scholar 

  • Marso SM, Bain SC, Consoli A, et al for the SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.

    Article  Google Scholar 

  • Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.

    Article  CAS  Google Scholar 

  • National Institute for Health and Clinical Excellence: Guidance. Obesity: Identification, Assessment and Management of Overweight and Obesity in Children, Young People and Adults: Partial Update of CG43. National Clinical Guideline Centre (UK). London: National Institute for Health and Care Excellence (UK); 2014.

    Google Scholar 

  • Ng M, Fleming T, Robinson M, Thompson B, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–81.

    Article  Google Scholar 

  • Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, Perez A, Smith SR. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315(10):990–1004.

    Article  CAS  Google Scholar 

  • O’Neil PM, Smith SR, Weissman NJ, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20(7):1426–36.

    Article  Google Scholar 

  • Padwal R, Kezouh A, Levine M, Etminan M. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes. 2007;31:1567–70.

    Article  CAS  Google Scholar 

  • Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. SCALE obesity and prediabetes NN8022-1839 study group. N Engl J Med. 2015;373(1):11–22.

    Article  Google Scholar 

  • Qsymia™ FDA prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/ label/2012/022580s000lbl.pdf. Accessed 15 Apr 2017.

  • Saxenda® FDA Advisory Panel Briefing Document. https://www.fda.gov/downloads/advisory committees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisory committee/ucm413317.pdf. Accessed 15 Apr 2017.

  • Saxenda® prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs /label/2014/206321Orig1s000lbl.pdf. Accessed 15 Apr 2017.

  • Schroll JB, Penninga EI, Gotasche PC. Assessment of adverse events in protocols, clinical study reports, and published papers of trials of orlistat: a document analysis. PLoS Medicine. 2016. https://doi.org/10.1371/journal.pmed.1002101.

    Article  Google Scholar 

  • Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–56.

    Article  CAS  Google Scholar 

  • Torgerson J, Hauptman J, Boldrin M, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.

    Article  CAS  Google Scholar 

  • Tran PT, Thomas A. Summary Minutes of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting March 28–29, 2012. http://www.fda.gov/downloads/AdvisoryCommittees /CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM303352.pdf. Accessed 15 Apr 2017.

  • Victoza® full prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022341s025lbl.pdf. Accessed 15 Apr 2017.

  • Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O’Neil PM, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–20.

    Article  CAS  Google Scholar 

  • Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443–51.

    Article  CAS  Google Scholar 

  • XENICAL prescribing information, US Food and Drug Administration. https://www.fda.gov/downloads-/UCM205349.pdf. Accessed 15 Apr 2017.

Download references

Acknowledgment

Supported in part by 1 U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health, which funds the Louisiana Clinical and Translational Science Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

Author information

Authors and Affiliations

  1. Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, USA

    Donna H. Ryan

  2. Department of Obstetrics and Gynecology, Louisiana State University School of Medicine, New Orleans, LA, USA

    Sarah R. Yockey

Authors
  1. Donna H. Ryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah R. Yockey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donna H. Ryan .

Editor information

Editors and Affiliations

  1. Department of Systems Medicine, Internal Medicine Unit and Obesity Center, University of Rome Tor Vergata, University Hospital Policlinico Tor Vergata, Rome, Italy

    Paolo Sbraccia

  2. National Centre for Cardiovascular Prevention, University College London, London, UK

    Nicholas Finer

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Ryan, D.H., Yockey, S.R. (2019). Medications Indicated for Chronic Weight Management. In: Sbraccia, P., Finer, N. (eds) Obesity. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-46933-1_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-46933-1_31

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-46932-4

  • Online ISBN: 978-3-319-46933-1

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation